Mergers and acquisitions of the biopharmaceutical industry and rising investment in research and development activity in the region have propelled the growth of the Asparaginase Market in the North America Region!
- Vikas Kumar
- July 13, 2023
- HEALTHCARE, NEWS
- 0 Comments
The Pharmaceutical industry has evolved and has been growing at a significant rate to ensure the delivery of high-quality products. For instance, According to the European Federation of Pharmaceutical Industries and Association in 2021, North America contributed to 49% of the sales, and 63.7% of the sales were generated from newly launched medicine. Additionally, the acquisition by the pharmaceutical industry to enhance the research activity wound positively enhance the growth of the market.
Access sample report (including graphs, charts, and figures):- https://univdatos.com/report/asparaginase-market/get-a-free-sample-form.php?product_id=40935
For instance, in May 2021, Jazz Pharmaceuticals acquired GW pharmaceutical company to enhance its R&D capabilities. In April 2021, Servier Pharamceuticals LLC completed the acquisition of Agios Pharmaceuticals for US$ 2 billion-plus royalties, including a commercial, clinical, and research-stage oncology portfolio. This acquisition strengthened Servier’s commercial presence in the US malignant haematology market and provides the potential for long-term growth in the solid tumor space. Also, product launch and approvals by the FDA for the treatment of acute lymphoblastic leukaemia is driving the market. For instance, In June 2021, Rylaze, a product by Jazz Pharmaceuticals, which is a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia (ALL) and lymphoblastic leukaemia (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase was approved by FDA. In July 2021, Jazz Pharmaceuticals launched Rylaze, a multi-agent chemotherapeutic regimen for the treatment of patients with ALL or LBL in pediatric and adult patients one month and older was launched in the United States.
FIG. 1 Asia Pacific Asparaginase Market Revenue (2020-2028)- USD Mn
For a detailed analysis of the Global Asparaginase Market browse through :- https://univdatos.com/report/asparaginase-market/
Based on application, the market is segmented into acute lymphoblastic leukaemia, acute myeloid leukaemia, and Other (Hodgkin’s disease). The acute lymphoblastic leukaemia segment is expected to grow with a high CAGR during the forecast period as a result of rising use in the treatment of lymphoproliferative disorders and lymphoma. For instance, According to the Institute of Health Metrics and Evaluation, in 2019 about 153,000 new cases of acute lymphoblastic leukaemia were reported globally. These are the elements that are anticipated to fuel the market during the forecast period.
Based on end-use, the market is segmented into hospitals, clinics, retail pharmacy, and online pharmacy. Hospitals held the dominant share of the market in 2021. The rapidly growing health infrastructure is expected to increase the demand for asparaginase, during the forecast period, leading to increase research activities, along with this rising investment in research and development by the key market players. For instance, in 2019 University of millions Chicago, secured funding of about USD 1 million for aspargine for the development of less toxic chemotherapy use in the treatment of ALL.
Global Asparaginase Market Segmentation
Market Insight, by Product
· Escherichia coli
· Erwinia chrysanthemi
· Pegylated
Market Insights, by Application
· Acute lymphoblastic leukaemia
· Acute myeloid leukaemia
· Other (Hodgkin’s disease)
Market Insights, by End-Use
· Hospitals
· Clinics
· Retail Pharmacy
· Online Pharmacy
Market Insight, by Region
· North America
o U.S.
o Canada
o Rest of North America
· Europe
o Germany
o UK
o France
o Italy
o Rest of Europe
· APAC
o China
o Japan
o India
o Rest of APAC
· Rest of the World
Top Company Profiles
· Jazz Pharmaceuticals plc
· Servier Pharmaceutical LLC
· medac GmbH
· Kyowa Kirin co, ltd.
· Taj Pharmaceuticals Limited.
· Creative Enzymes.
· Bio Vendor R&D
· Gennova Biopharmaceuticals Limited.
· Actiza Pharmaceutical Private Limited
· Porton Biopharma
